In Japan, on the other hand, eribulin has been approved for the treatment of patients with inoperable or recurrent breast cancer but not limited to those who have been previously treated with chemotherapy regimens for MBC.A phase II study of eribulin in Japanese patients with locally advanced disease or MBC who were hormone receptor and HER2 positive as well as previously treated with an anthracycline and a taxane, eribulin demonstrated an OS of 11.1 months, respectively (Aogi et al. 2012). The gene discussed is ERBB2; the disease is breast carcinoma.